A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Trial Profile

A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat inhaler, after 4 weeks of once daily [5 Mcg in the evening (2 actuations of 2.5 Mcg)] or twice daily [2.5 Mcg in the morning and evening (2 actuations of 1.25 Mcg)] administration in patients with moderate persistent asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 03 Apr 2013 Planned number of patients changed from 92 to 98 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top